Research
Adherence
Early weight loss (≥5%) within 12-16 weeks is the only consistent predictor of long-term efficacy for obesity pharmacotherapy in polygenic obesity, justifying the discontinuation of ineffective medications.
When starting a new obesity medication, expect to be evaluated at 12-16 weeks. If you haven't lost at least 5% of your body weight by then, your doctor will likely stop the medication. This is not a failure on your part, but a standard safety and efficacy check to switch to a different treatment.
StrongQualifiesHIGH confidence
Early treatment response (weight loss at 16 weeks) is the only factor consistently associated with longer-term weight outcome [43, 44], hence regulatory authorities recommend stopping most obesity medications if less than 5% weight loss has been achieved after 12-16 weeks, but this does not assist with the initial choice of medication.
Why this rating
Supported by multiple studies cited as consistently associating early response with long-term outcome.
Source
Individualised prescription of medications for treatment of obesity in adults
Samantha Hocking et al. · Reviews in Endocrine and Metabolic Disorders · 2023
DOI 10.1007/s11154-023-09808-2
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- For polygenic obesity, precision medicine approaches targeting specific genetic variants or phenotypes have not yet translated into reliable clinical guidance for selecting obesity medications, making early weight loss response the only consistent predictor of long-term efficacy.Good
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →